Which 5-fluorouracil regimen? The great debate

Anti-Cancer Drugs

Volumn 10, Issue 4, 1999, Pages 337-354

  Vincent, Mark ^a,c   Labianca, Roberto ^a   Harper, Peter ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b OSPEDALI RIUNITI   (Italy)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

5 fluorouracil; Advanced colorectal cancer; Regimens; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; FLUOROURACIL; FOLINIC ACID;

COLON TUMOR; COLORECTAL TUMOR; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; RECTUM TUMOR; REVIEW;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; LEUCOVORIN; RECTAL NEOPLASMS;

EID: 0033113876     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199904000-00001     Document Type: Article

References (85)

1. EstèveJ, Kricker A, FerlayJ, Parkin DM. Facts and figures of cancer in the European Community. Lyon: International Agency for Research on Cancer 1993-
2. Boring CC, Squires TS, Tong T, Montgomery S. Cancer Statistics, 1994. ÇA Cancer] Clin 1994; 44: 7-26.
3. Cunningham D, Zalcberg JR, Rath U, et al. Final results of a randomised trial comparing Tomudex'1' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 1996; 7: 961-5.
4. Bleiberg H. Colorectal cancer-is there an alternative to 5FU? EiirJ Cancer 1997; 33: 536-41.
5. Rustum YM, Harstrick A, Cao S, et al. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors./C7/w Oncol 1997; 15: 389-400.
6. Touroutoglou N, Pazdur R. Thymidylate synthase inhibitors. Clin Cancer Res 1996; 2: 227-43.
7. Labianca R, Pessi A, Facendola G, Pirovano M, Luporini G. Modulated 5-fluorouracil (5-FU) regimens in advanced colorectal cancer: a critical review of comparative studies. EnrJ Cancer 1996; 32A (suppl 5): S7-12.
8. Moertel CG. Chemotherapy for colorectal cancer. N Engl JMed 1994; 330: 1136-42.
9. Seymour MT, Stenning SP, Gissidy J on behalf of the Colorectal Cancer Working Part)' of the UK Medical Research Council. Attitudes and practice in the management of metastatic colorectal cancer in Britain. Clin Oncol 1997; 9: 248-51.
10. Ross P, Webb A, Cunningliam D, et al. Chemotherapy for colorectal cancer relationship between toxicity and quality of life. Ann Oncol 1996; 7 (suppl 5): 34 (abstr 1540).
11. Redmond K. Assessing patients' needs and preferences in the management of advanced colorectal cancer. Br J Cancer 1998; 77 (suppl 2): 5-7.
12. Topham C. A survey of patients' perceptions of the convenience of different chemotherapy regimens for advanced colorectal cancer. EnrJ Cancer Care 1997; 6: 208-11.
13. Wils J, Sahmoud T, Sobrero A, et al. Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG. European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Timiori 1998; 84: 335-47.
14. DeVita VT Jr. Principles of cancer management: chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology, 3rd edn. Philadelpliia: Lippincott-Raven 1997: 333-47.
15. Byrne M. Cancer chemotherapy and quality of life. Br MedJ 1992; 304: 1523-4.
16. Moinpour CM, Feigl P, Metch B, Hayden KA, Meyskens FL Jr, CrowleyJ. Quality of life end points in cancer clinical trials: review and recommendations. / ffatl Cancer Inst 1989; 81: 485-95.
17. Labianca R, Pancera G, Aitini E, et al. Folinic acid + 5fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of 'GISCAD' (Italian Group for the Study of Digestive Tract Cancer). Ann Oncol 1991; 2: 673-9-
18. O'Connell MJ. A phase III trial of 5-fluorouraciI and leucovorin in the treatment of advanced colorectal cancer a Mayo Clinic/North Central Cancer Treatment Group Study. Cancer 1989; 63: 1026-30.
19. Petrioli R, Lorenzi M, Aquino A, et al. Treatment of advanced colorectal cancer with high-dose intensity folinic acid and 5-fluorouracil plus supportive care. Enr J Cancer 1995; 12: 2105-8.
20. Lokich JJ, Alilgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a MidAtlantic Oncology Program study. / Clin Oncol 1989; 7: 425-32.
21. Leichman CG, Fleming TR, Muggia FM, ct al. Phase U study of fluorouracil and its modulation in advanced colorectal cancer, a Southwest Oncology Group study. / atn Oncol 1995; 13: 1303-11.
22. Eriichman C, Fine S, Wong A, Elhakim T. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988; 6: 469-75.
23. Bobbio-Pallavicini E, Porta C, Moroni M, Spaglii A, Casagranda I, Nastasi G. Folinic acid does improve 5fluorouracil activity in vivo. Results of a phase III trial comparing 5-fluorouracil to 5-fiuorouracil and folinic acid in advanced colon cancer patients./ Cbemother 1993; 5: 52-5.
24. Doroshow JH, Multhauf P, Leong L, et al. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy./ Clin Oncol 1990; 8: 491-501.
25. Hansen RM, Ryan L, Anderson T, et al. Phase m study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. / Natl Cancer Iiist 1996; 88: 668-74.
26. Macliiavelli M, Leone BA, Romero A, et al. Advanced colorectal carcinoma: a prospective randomized trial of sequential methotrexate, 5-fluorouracil, and leucovorin versus 5-fluorouracil alone. Am J Clin Oncol 1991; 14: 211-7.
27. Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and liigh-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. / Clin Oncol 1987; 5: 1559-65.
28. Di Costanzo F, Bartolucci R, Calabresi F, et al. Fluorouracil alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer a randomized trial of the Italian Onclology Group for Clinical Research (GOIRQ. Ann Oncol 1992; 3: 371-6.
29. Valone FH, Friedman MA, Wittlinger PS, et al. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group./C7/H Oncol 1989; 7: 1427-36.
30. Aranda E, Cervantes A, Carrato A, et al. for the Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD). Ann Oncol 1996; 7: 581-5.
31. Beerblock K, Rinaldi Y, André T, et al. for the Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma. Cancer 1997; 79: 1100-5.
32. Blijham G, Wagener T, Wils J, et al. Modulation of highdose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer final results of a randomized European Organization for Research and Treatment of Cancer Study. / Gin Oncol 1996; 14: 2266-73.
33. BurokerTR, O'Connell MJ, Wieand HS, etal. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. / Gin Oncol 1994; 12: 14-20.
34. Caudry M, Bonnel C, Floquet A, et al. A randomized study of bolus fluorouracil plus folinic acid versus 21-day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma. Am J Clin Oncol 1995; 18: 118-25.
35. Corfu-A Study Group. Phase HI randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. / Clin Oncol 1995; 13: 921-8.
36. Wacller S, Schwanz EL, Goldman M, et al. Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. / Clin Oncol 1989; 7: 1769-75.
37. de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer a French intergroup study. / Clin Oncol 1997; 15: 808-15.
38. Hanna CL, McKinna FE, Williams LB, et al. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer poor response rate in unselected patients. BrJ Cancer 1995; 72: 774-6.
39. Hill M, Norman A, Cunningham D, et al. Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer./ Clin Oncol 1995; 13: 2317-23.
40. Jäger E, Heike M, Bernhard H, et al for the Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. Weekly liigh-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer, results of a randomized multicenter trial. J Clin Oncol 1996; 14: 2274-9.
41. Köline CH, Schöffski P, Wilke H, et al. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer./ Clin Oncol 1998; 16: 418-6.
42. Machover D, Goldschmidt E, Chollet P, et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5fluorouracil and high-dose folinic acid. NCI Monogr 1987; 5: 193-8.
43. Poon MA, O'Connell MJ, Wieand HS, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991; 9: 1967-72.
44. Reccliia F, Nuzzo A, Lalli A, et al. Randomized trial of 5fluorouracil and high-dose folinic acid with or without alpha-2B interferon in advanced colorectal cancer. Am J Clin Oncol 1996; 19: 301-4.
45. Seymour MT, Slevin ML, Kerr DJ, et al. for the Colorectal Cancer Working Party of the United Kingdom Medical Research Council. Randomized trial assessing the addition of interferon a-2a to fluorouracil and leucovorin in advanced colorectal cancer. / Clin Oncol 1996; 14: 2280-8.
46. Scheithauer W, Depisch D, Kornek G, et al. Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer. Cancer 1994; 73: 15628.
47. Weh HJ, Wilke HJ, Dierlamm J, et al. Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24hour infusion in ptretreated patients with metastatic colorectal carcinoma. Ann Oncol 1994; 5: 233-7.
48. Ardalan B, Chua L, Tian EM, et al. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorcctal carcinoma./ Clin Oncol 1991; 9625-30.
49. Goldberg RM, Hatfield AK, Kaiin M, et al. Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the lisomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer./ Clin Oncol 1997; 15: 3320-9.
50. Labianca R, Cascinu S, Frontini L, et al. on behalf of GISCAD (Italian Group for the Study of Digestive Tract Cancer). High- versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer a 'GISCAD' phase m study. Ann Oncol 1997; 8: 169-74.
51. Laufman LR, Bukowski RM, Collier MA, et al. A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. / Clin Oncol 1993; 11: 1888-93.
52. Grem JL Systemic treatment options in advanced colorectal cancer perspectives on combination 5-fluorouracil plus leucovorin. Semin Oncol 1997; 24 (suppl 18): 8-18.
53. Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. / Clin Oncol 1989; 7: 1407-17.
54. Machover D, Schwarzenberg L, Goldschmidt E, et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: a pilot study. Cancer Treat Rep 1982; 66: 1803-7.
55. iMadajewicz P. Phase I/II trial of liigh-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer. Cancer Res 1984; 44: 4667-5669.
56. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer, evidence in terms of response me. J Clin Oncol 1992; 10: 896-903-
57. Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer-a tale of two drugs: implications for biochemical modulation. / Clin Oncol 1997; 15: 368-81.
58. Lokich J. Protracted infusional 5-fluorouracil for colorectal cancer. Tinnori 1997; 83 (suppl): S53-5-
59. Seifen P, Baker LH, Reed MD, Vaitkevikius VK. Comparison of continuously infused 5-fluorouracil with bolus injection in patients with colorectal adenocarcinoma. Cancer 1975; 36: 123-8.
60. Aschele C, Guglielmi A, Frassineti GL, et al. Scheduleselective biochemical modulation of 5-fluorouracil in advanced colorectal cancer a multicentric phase II study. BrJ Cancer 1998; 77: 341-6.
61. Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. -J Clin Oncol 1998; 16: 301-8.
62. Tliirion P, Cunningham D, Findlay M, et al. Pooled analysis of phase II trials with low-dose 5-fluorouracil continuous infusion (LD 5-FU CI) as a second line chemotherapy in advanced colorectal cancer (ACQ. Proc Am Soc Clin Oncol 1998; 17: 272a (abstr 1047).
63. de Gramont A, Louvet C, André T, Toumigand C, Krulik M, from tlie Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire and Digestifs (GERCOD). A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer evolution of a regimen. EurJ Cancer 1998; 34: 619-26.
64. de Gramont A, Krulik M, Cady J, et al. Higli-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol 1988; 24: 1499-503.
65. Sobrero A, Labianca R, Frassineti GL, et al. Randomized comparison between methotrexate-fluorouracil and schedule-specific biochemical modulation in advanced colorectal cancer. ProcAm Soc Clin Oncol 1997; 16: 272a (abstr 964).
66. Cohen AM, Minsk)' BD, Scliilsky RL Cancer of the colon. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancelprinciples and practice of oncology, 5th edn. Pliiladelphia: Lippincott-Raven 1997: 1144-97.
67. Tomiak A, Vincent M, Kocha W, et al. Standard dose (Mayo regimen) 5-FU and folinic acid: prohibitive toxicity? ProcAm Soc Clin Oncol 1998; 17: 276a (abstr 1062).
68. Bonier MM, Castiglione M, Bacclii M, et al. The impact of adding low-dose leucovorin to montlily 5-flurouracil in advanced colorectal cancer, results of a phase III trial. Ann Oncol 1998; 9: 535-41.
69. Diasio RB, Beavers TL, Carpenter T. Familial deficiency of dihydropyrimidine dehydrogenase: biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity./ Clin Invest 1988; 81: 47.
70. \nn Triest B, van Groeningen CJ, Pinedo HM. Current chemotherapeutic possibilities in the treatment of colorectal cancer. EurJ Cancer 1995; 31A: 1193-7.
71. Jodrell DI, Murray LS, Reed NS, Canney PA, Kaye SB, CassidyJ. Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK? BrJ Cancer 1994; 70: 749-52.
72. Wils J. The establishment of a large collaborative trial programme in the adjuvant treatment of colon cancer. Br J Cancer 1998; 77 (suppl 2): 23-8.
73. QUASAR. A UKCCCR study of colorectal cancer treatment. Oxford: QUASAR Office, Clinical Trials Service Unit, Radcliffe Infirmary 1996.
74. Armand J, Ducreux M, Mahjoubi M, et al. CPT11 (irinotecan) in the treatment of colorectal cancer. EurJ Cancer 1995; 31Ä: 1283-7.
75. Rougier PH, Bugat R. CPT-11 in the treatment of colorectal cancer clinical efficacy and safety profile. Semin Oncol 1996; 23: 34-41.
76. Van Cutsem E, Cunningham D, Ten Bokkel Huinink W, et al. Irinotecan (CPT-11) multicenter phase II study in colorectal cancer patients with documented progressive disease on prior 5FU: preliminary results. Proc Am Soc Clin Oncol 1996; 15: 562.
77. Becouran Y, Ychou M, Ducreux M, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. / Clin Oncol 1998; 16: 2739-44.
78. Diaz-Rubio E, Many M, Extra JM, et al. Multicentric phase II study with oxaliplatin (L-OHP11) in 5-FU refractory patients with advanced colorectal cancer. Proc At n Soc Clin Oijcol 1995; 14: 209 (abstr 514).
79. de Gramont A, Figer A, Seymour M, et al. A randomized trial of leucovorin (LV) and 5-fluorouracil (5FU) with or witliout oxaliplatin in advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 1998; 17: 257a (abstr 985).
80. Cocconi G, Cunningham D, Van Cutsem E, et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group./ din Oncol 1998; 16: 2943-52.
81. Dragnev KH, Schwanz J, Bertino N, et al. Interim results of a phase I trial suggest that Tomudex (raltitrexed) may act synergistically with 5-fluorouracil (5-FU) in patients with advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol 1998; 17: 225a (abstr 868).
82. Harstrick A, Mayer S, Müller C, et al. Combination therapy with infusional 5-FU and 'Tomudex' for patients with advanced colorectal cancer-a phase I study. Proc Am Soc Clin Oncol 1998; 17: 200a (abstr 772).
83. André T, de Gramont A, Louvet C, et al. Bimonthly CPT11 with leucovorin (LV) and 5-fluorouracil (5-FU) in pretreated metastatic colorectal cancer (FOLFIRI)- Proc Am Soc Clin Oncol 1998; 17: 273a (abstr 1051).
84. Ardalan B, Singh G, Silberman H. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without A phosphonacetylX-aspartic acid in patients with advanced pancreatic and colorectal cancers. / Clin Oncol 1988; 6: 1053-8.
85. Buechele T, Schoeber C, Kroening H, et al. Weekly highdose (HD) 5-fluorouracü (5-FU) and folinic acid (FA) with addition of oxaliplatin (LOHP) after documented progression under high-dose infusional 5-FU/FA in patients (PTS) with advanced colorectal cancer (CRQ. Proc Am Soc Clin Oncol 1998; 17: 287a (abstr 1106).